Clinical Trial

IASO104 for the Treatment of Patients With Relapsed/Refractory Multiple Myeloma

Study acronym: IASO104
Not Yet Recruiting Early Phase 1
View on ClinicalTrials.gov →
Summary
This study is a single-center, open-label, dose-exploration trial designed to evaluate the tolerability and safety of different doses of IASO104 in patients with relapsed/refractory plasma cell neoplasms, determine the recommended dose of IASO104, and assess its pharmacokinetic and pharmacodynamic characteristics. Additionally, the study will preliminarily observe the efficacy of the investigational drug in a small sample of subjects with relapsed/refractory multiple myeloma.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-09-15.
Trial Details
NCT Number NCT07185490
Lead Sponsor Institute of Hematology & Blood Diseases Hospital, China
Conditions Relapsed/Refractory Multiple Myeloma (RRMM), Plasma Cell Leukemia (PCL)
Enrollment 40 participants
Start Date 2026-02-15
Primary Completion 2027-08-15 (estimated)
Study Completion 2029-08-15 (estimated)
Updated on ClinicalTrials.gov 2026-01-20